Pharmacologic properties of new guanidine and azepine derivatives.
D000818:Animals; D000893:Anti-Inflammatory Agents; D000917:Antibody Formation / Q000187:drug effects; D001168:Arthritis / Q000188:drug therapy; D001381:Azepines / Q000494:pharmacology / Q000627:therapeutic use / Q000633:toxicity*; D002462:Cell Membrane / Q000187:drug effects; D004353:Drug Evaluation, Preclinical; D004912:Erythrocytes / Q000187:drug effects; D006146:Guanidines / Q000494:pharmacology / Q000627:therapeutic use / Q000633:toxicity*; D006168:Guinea Pigs; D007166:Immunosuppressive Agents; D007928:Lethal Dose 50; D011817:Rabbits; D051381:Rats
D000893:Anti-Inflammatory Agents; D001381:Azepines; D006146:Guanidines; D007166:Immunosuppressive Agents